Molecular characterisation, expression and localisation of human neurokinin-3 receptor  by Buell, G. et al.
Volume 299, number 1, 90-95 FEBS 10793 
© 1992 Federation of European Biochemical Societies 00145793192/$5.00 
March 1992 
Molecular characterisation, expression and localisation of human 
neurokinin-3 receptor 
G. Buell, M.F. Schulz, S.J. Arkinstall, K. Maury, M. Missotten, N. Adami, F. Talabot and E. Kawashima 
Glaxo lnstitutejbr Molecular Biology, 14 chemin des Aulx, Case Pustule 674, 1228 Plan-les-Ouates, 1211 Geneva, 24, Sw#zerland 
Received 14 January 1992 
The complete amino acid sequence of the human neurokinin-3 receptor was deduced by DNA sgqumtco analysis of human genomic fragments. 
Comparison of the predicted primary structure with those for the human neurokinin receptors 1and 2 shows a highly conserved pattern of seven 
hydrophobi¢ regions with maximum divergence oceuring at the amino- and carboxy-terrnini, The position of intron-exon junctions are identical 
to those in other reported neurokinin genes, Using a chimeric genomic.cDNA gone, the human NK-3 receptor was expressed in Xenopus laevts 
oooytes where it mediates membrane conductance hanges in response to its agonist, neurokinin B. More significantly, expression of the 8ene in 
mammalian cells resulted in detection of receptor binding as well as neurokinin-stimulated calcium mobilization and araehidonie acid release, all 
displaying the pharmacological haracteristics expected of a nearokinin-3 receptor, By using the polymerase chain reaction we have shown that 
mRNA for the human eurokinin-3 receptor is expressed predominantly in the egntral nervous ystem, 
Neurokinin; Ncurokinin-3 re.~ptor (human); Brain localization; Calcium mobilization; Arachidonie acid release 
I. INTRODUCTION 
Neurokinins are a family of neuropeptides displaying 
wide-spread distribution and diverse biological ac- 
tivities including regulation of neurotransmission, in- 
flammation and perception of pain [1-3]. Substance P 
($P), neurokinin A (NKA) and neurokinin B (NKB) are 
mammalian neurokinins showing limited selectivity 
towards, respectively, NK-1, NK-2 and NK-3 re- 
ceptors. Pharmacological and biochemical studies, as 
well as molecular cloning, have shown that all three 
neurokinin receptors are members of the G-protein- 
coupled receptor super-family possessing seven putative 
transmembrane r gions [4]. 
NK-3 receptors have been identified in membranes 
from guinea pig myenteric plexus and cerebral cortex [5] 
as well as brain slices of rat, mouse and guinea pig 
[2,3,6,7]. NK-3 receptors also mediate increased phos- 
phoinositide hydrolysis in guinea pig ileum and neona- 
tal rat spinal cord [2,8]. In addition, NK-3 receptors 
depolarize guinea pig myenteric neurons to augment 
release of acetyleholine [9-11], stimulate contraction of 
the rat portal vein [12] and modulate both serotinergie- 
and ¢holinergic-dependent behavioural responses in 
mouse and rat [13,14]. Despite these observations indi- 
cating an important physiological role controlling 
transmitter elease and vascular tone in some species, 
NK-3 receptors have not been identified in human tis- 
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sues. Moreover, a recent study employing radioligand 
binding to brain slices failed to detect NK-3 receptors 
in either monkey or human [6]. To answer definitively 
the question of whether the NK-3 receptor is expressed 
in human tissues, we set out to detect and identify mole- 
cularly the NK-3 gene as well as to loealise and char- 
acterise pharmacologically, the receptor itself. 
2. MATERIALS AND METHODS 
2.1. Materials 
NKB, NKA and SP were purchased from Bachem. The human 
genomic lambda bank was purchased from Clontech as was the fetal 
human brain eDNA bank used for amplification of NK-3 eDNA, The 
plasmids peR 1000, used to clone amplified DNA and PeDNA-I 
NEe were purchased from lnvitrogen. 
2.2. Tissues 
Human brain from a deceased 76.year-old patient was obtained 
from Dr, C, Bourns (University of Geneva), Between 0.3 and 1,0 g of 
brain tissue was dissected from various neuroanatomical areas as 
descril:~l in the text, Pieces of peripheral tissues (0,2-1.0 g) removed 
during surgery and frozen quickly at -70"C were obtained from Dr. 
A,-P. Supine (Hospital Cantonal, University of Geneva), 
2.3. Gene isolation 
Detection and analysis of recombinant phage was essentially as 
described previously [1S]. Most t~hniques, including random pritner 
labelina, Southern blotting, dideoxy sequencing, ligation, plasmid 
DNA isolation and polymerase chain reaction (PER) were done by 
standard protocols [16], Sequence alignments, hown in Fig. 3 were 
made using 'Pileup' [17]. 
2,4, Oocyte lectrophysiology 
Ooeytes of Xenopus laevts at stage VI were prepared by incubation 
with 0.2% collagenase in OR-2 medium without calcium. Occyte 
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nuclei were injected with 10 nl of injection buffer (88 mM NaCI/I mM 
KCI/15 mM HEPES, pH 7.0) containing 1ng of plasmid DNA. After 
injection, oocytes were kept at 19"C in OR-2 medium supplemented 
with 100 units of penicillin, 100/ag of streptomycin, and 20/zg of 
kanamycin l~r ml for 1-3 days before being tested ¢iectrophysiologi- 
c.ally [18]. 
2.5. ClIO cell expression, radioltgaad bfnding and intracellular calcium 
measurements 
The chimeric NK-3 genomic-cDNA gen~ was ligated to the vector 
pBGL312 for transfcction i  Chinese Hamster Ova,T (CHO) ceils. 
pBGL312 is a derivative of pBG312 [19] containing resistance gen~ 
for both G418 and methotr~xate. One transfected CHO cell clon¢ 
resistant to 400/~g/ml G418 was grown in 6-well plates (1-2 x 106 cells), 
washed twice with phosphate-buffered saline and incubated at 37°C 
in 0.5 ml of Dulbecco's Modified Eagles medium/Ham's F-12 (v/v) 
medium (Gibeo, Paisley, Scotland, UK) supplemented with 0,6 mM 
MnCI2, 0.004% (w/v) BSA and containing [~lTJSenktide (NEN; specific 
activity 83.1 Ci/mmol) and other ncurop©ptides as indicated. After 60 
rain, cells were washed twice with ice.cold medium (ligand-free), so- 
lubilized using 5% (w/v) gDS and bound [~H]Senktide termined by 
scintillation spectrometry. For saturation analysis non-specific bind- 
ing was measured in the presence of 1/aM NKB. Intracellular Ca 2~ 
concentrations were determined using the fluorescent Ca 2. chelator 
furs2 (Calbiochem) exactly as described [20]. 
2.6. RNA isolation and PCR analysis 
Total RNA was ©ztracted from each tissue by the method of 
Chomczynski and Sacohi [21]. A 10/ag sample of total RNA was used 
for the synthesis of eDNA with random primers and AMV reverse 
transcriptase in a total volume of 20/al. PCR amplification was per- 
formed in 100/~! reactions containing 4/zl of eDNA and primers at 
1 raM, The following primers were used (s0¢ Fig. 1A): 
primer 1: (5')-GGTGGAGGCGTGGGTGCAGACG 
primor 2: (5')-CACTTACCATATTATGCTCATTATACTGG 
primer 3: (5")-GGGTATATAGGACAGGACTGATAAA 
The PCR was carried out for 30 cycles by heating at 94°C for 1 min, 
followed by annealing at 60°C for 2 min and elongation at 72°C for 
3 rain. 5/zl of each reaction was loaded on a 0.8% agaroso gel after 
¢lcctrophorcsis and transferred to Gcne$crcen Plus (NEN) filters. All 
cDNA samples were also compared for equivalency by PCR with 
actin-specific primers (not shown). 
3. RESULTS AND DISCUSSION 
Because prior pharmacological nalysis or radio- 
ligand binding studies had not identified any human 
tissues as positive for NK-3 receptor expression, we 
chose to screen a human genomic bank and to clone all 
of the exons encoding the translated portions of NK-3. 
The obtained sequences permitted the design of human 
NK-3 specific PCR primers and subsequently the am- 
plification of NK-3 eDNA. 
Screening of 5 × 10 s recombinant phage, bearing in- 
serts of human genomic DNA generated three can- 
didates that strongly cross-hybridized with rat NK-3 
eDNA [22]. DNA prepared from these phage was 
analyzed by Southern blotting and fragments were 
chosen for subc!oning into pUCI9 (Fig. IA). Based on 
sequence comparison with other neurokinin genes [22- 
26], we concluded that the fragments contained all of 
the human NK-3 vxons corresponding to translated 
portions of the gene with the exception of the first 17 
bp of exon 2. The intron--cxon boundaries in human 
N K-3 conform in position to other NK genes. Sequence 
information for the combined exom is shown in Fig. lB. 
This Segluence begins with a naturally occurring Pstl 
site, 16 bp upstream from the codon for the initiating 
methionine and ends with an Xbal site which is the 
original terminus of the 3500 hp XbaI fragment that 
contains exons 4 and 5. 
PCR primers were designed to several parts of the 
human NK-3 sequence and tested on a variety of eDNA 
templates. In no case were we able to generate a full- 
length eDNA copy using primers 1 and 3 (Fig. IA), 
corresponding to the all of the oxen sequences. The 
longest PCR product, generated for human NK-3, came 
from a fetal brain eDNA template and primers whose 
positions are shown in Fig. IA. This 941 bp fragment 
contains the last 24 bp of exon 1 and all of the exons 
2, 3, 4 and 5. The fragment was cloned and its sequence 
confirmed that shown for the exon sequences a  well as 
the exon-intron junctions. 
Comparison of the amino acid sequences for the three 
human eurokinin receptors (Fig. 2) shows a maximum 
conservation of sequence in the putative transmem- 
brane regions and a minimal identity at the amino- and 
carboxy-termini. One exception isthe region shown be- 
tween transmembrane region I and If, which is also 
highly conserved between the three proteins. Closer in- 
spection also permits one to identify some transmvm- 
brane regions (TMVII) as more conserved than o~,hers. 
Overall, the amino acid sequence of human NK-3 has 
74% and 68% homology with the sequences for human 
NK-I and NK-2. 
In order to confirm that the genomic sequence on- 
codes a human NK-3 receptor we prepared a chimeric 
gene by ligating the PCR amplified eDNA to a fragment 
ofexon 1 DNA, This was simplified u¢ to the pr~en~ 
of a unique site for BstXI in both the eDNA and exon 
1 DNA. The chimeric gene (shown schematically in Fig. 
1A) was subcloned in the plasmid pcDNA1-NEO or 
pBGL312 and investigated in a series of functional as. 
says, 
We began using ¢lectrophysiology to test for NK-3 
receptor mediated functional activity 2 days after the 
plasmid pcDNA1-NEO was injectcx! into nuclei of 
Xenopus laevis oocytes. Neurokinins increased current 
amplitude (data not shown) with the relative rank-order 
of potency: NKB>NKA>SP which is consistent with 
the actions of an NK-3 receptor [2,11,12,28]. Half-max- 
imally effective concentrations of NKB and NKA were 
4 nM and 40 nM, respectively. A reversal potential of 
-30 mV, close to the equilibrium potential for chloride, 
indicates that a Ca~%sensitive chloride channel is ac- 
tivatext [27]. 
We next expressed the NK-3 receptor gone in CHO 
cells using plasmid pBGL312 with one G418-resistant 
subclone mployed in all experiments. [~HJSenktide was 
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¢T~¢AGA~CGGT~GC~TG~ATc~CAG~A~A~TGGATAGACGGGGGTQGAGG~GTGGGTGC~GAG~cGT~¢¢TGA~CGC~T~cTA 
1~ta~A~aZ~eLQuP~G~Th~T~pZ~e~pG1~G~G~Va~G~A~aAs l~A~Va~AsnLeuTh~A~&Se~Lou 20 
GcTGCCGGG~GGC~CGG~GGcAGTTGAGAcTGGGTG~cT~G~TG~Ac~AAGCTGG~AAccTCTccTC~Tccc~TTccGcGcTGGGA~TGc~TG 
A~aG~A~aA~aTh~G~A~aV~G~uTh~G~T~PLeuG~nLeuLouA~G~nA~nL~u~e~aE~e~P~o~A~a;Mu~YLeuP~oV~ G2 
TGC~TTCCc¢~G~G¢C¢Tcc~Gc~TG~C~%A~TcAc~c~AGTT~GTG~A~TC~TGG~GTAT~G~G~T~TG~TCC~T~T~TGGTGTGGT 
A~Se~P~A~&~GseE~nP~T~pA~nLeuT~nG~nPheV~G~nP~se~TEp~E~A~aLe~T~Pse~L i~1A~aT~G1~Va~V~ 9S 
GGTGG~AGTGG~AGTTTT~G~AR~T~TCAT~GTCATC~GGATC~T~CTGG~C~AGCGCJ%T~G~T~T~¢~%J~TAcTTc~TT~T~RA~cTGG~T 
Vn~aV&~RA~v~u~y~snL~eV&~eT~PZ~e2~eLeuA~aHisL~sA~gN~gTh~V~Th~AsnT~PheLeuV&~n~evJ~a i~  
~TCT¢C~C~C~T~CJ~T~G~TT~A~A~GTTGGT~AATTT~AT¢TA~G~TTCATAG~GAGT~GT~TTT~GCG~AR~T~CTGc~G~TT~AG~ 
P~eS~A~A~a~e~A~a¥heA~nTh~L~uVa~A~n~heZ~eT~A~LeuHL~Se~G1~T~PT~Phe~nT~c~A~P~eG~nAsn ~62 
~CTT~TTT~TATCJ~AGCTGTGTT~GCC.AG¢ATCTA~Tc~J~T~ACGGc~ATTGCG~c~a~a~a~a~a~g~a~aaa~a~ 
PhePh~PEo21eThEAlaV&iP~e~laSeE~leT~ESeEM~T~EAl~Ile~l~Vi~p~Eg Z~T~OH ~ ~83 
GGTATATG~CTATTATTG~TCCC~TGA~%CCCAGACTGTCTGCTA~CAA~Q~TTGT~ATTGGAA~TATTTGGAT 
T~e~-A~n~e2~e`~=P~Le~L~ePz~A~L~u~EA~ThEA~aT~Ly~Z~V~Z~G~yseE~eT~P~e 20~ 
TCTAGCJ~TTT~TACT~CTT~¢~Tc~TGT~TTT~TT~%~A~c~A~G~cATG¢~GG~GTAcTcTCTG~TTTGTGCARTG~CAGA~GGT~CCA~J~ 
Le~A~aPh~LeuLe~J~&¥~e¥E~G~n~Le~T~S~L~T~L~V&~G~hE;*e~sPheVn~G~nT~P~uG~P~L~s 242 
GlnHL~PheT~E T~EHL~ 24~ 
TAT~AT~GT~ATTATA¢TG~T~T~¢T~TTT¢ccATTGcTCAT~AT~GG~A~TA~ATA~A~ATTGTTG~TTAcT~T~TGGG~A~AT~CA~A 
2~e~eV~e~eL~uV~T~P~e¥~LeuLeu~e14e~G~eTh~T~EThE~a~G~Z~eTh~uT~G~G~eP~G~ 20~ 
GATACCTGTGA~AAGTATCATGAGCAGCTAAP.GGCCAAAAGAA~G~IO~OO~g~=ig  ~NTRON C u~&a~a~ 
~pT~EC~sA~pLyaTyE~L~GIuGInLe~y~A~Ly~L~s Z~6 
t~&~a~GTTGTC~AATGATG~TT~TTGTTGT~TGA¢ATTTGcTATcTG~TGGcT~cc~TATCATATTTA~TT~AT~T~A~TGCAATCTAT~ 
Va~V~L~e~e~Z~e~V~Va~Me~T~Ph~tA~a~T~p~uP~T~H~s~T~Z~aLGuT~EA~eT~EG~n 32~ 
~cAA~TAAATAQATGGA~ATA~AT~AG~3GTcT~cTG~TAG~TTTTGG~TGG~RATG~G~TC~CATGT~CA~T~CC~T~TCTA~TGCTGT~T 
G~nL~sn~T~pL~=Ty~Z~eG~nV&~T~z~e.~A~Se~PheT~p~e~&~e~Se~s~Th~Me~T~AsnP~eZ~eT~c~sc~Leu 359 
AsnL~A~ ~2 
~a~ATTT~GA~T~TT~RAG~AGcATTTC~CTGGTGTccTT~ATcRJ1A~TTTccA~cTATQ~TGA~TAGAGcTcR~A~CAC~GTTT~A~¢C 
Ph~A~A~aG~¥h~y~A~h~A~TE~P~e~eL~V~e~e~T~u~P~uLeuG~uLe~L~sThET~A~h~ 394 
A~C~GG~G~TATGT~A~CGTG~C~AQ~T~AGT~TG~c~T~GT~TTT~c~A~C'~TGcA~AccAcc~GTc~TcGC' J~AG~A 
A~n~G~nse~SeEMe~T~Th~va~Th~A~G~uSe~M~T~V~V~P~sp~As~A~J~T~Th~At~e~A~L~L~ 42~ 
RG~GcA~GccAAGA~Ac~cAAGTTTcAATGG~TG~Tc~cGcAG~AATT~A~ATcTG~T~GC~ACTT~AAGTTT~AT~CTC~C~%.ATA~CTCTG 
AE~A~T~EPE~E~As~P~e~nG~C~se~AE~A~n~e~L~e~A~Se~A~=Th~se~S~heZ~eSe~Se~P~T~EThE~i~V~ 4~I 
< . . . . .  ~R~I ,~ . . . . . . . .  < 
T~C~TG~T~TT~T~.~S~TT~TTT~CTGAGGTAAA~GATT~GTG~GACCATcATGGT~CCAGTcTAGGACCC~ATT~T~CTATT~AT~AG~CCTGTC 
A~GIuT~u~eE ~65 
CTAT~.TACCCTCTA,C*A 
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Fig. I. (A) Schematic diagram for the isolation of NK-3 exon contain- 
ing fragments. NK-3 exon I was isolated on a 3000 hp Xb,,l fragment. 
gxons 2 and 3 were isolated from the same phage as I ~00 bp Sa/l and 
2000 hp Xbal fragments, respectively. Exons 4 and 5 were isolated 
together on a 3500 bp ::hal fragrncnt. The chimeric NK-3 gene was 
constructed by iigating a PstI.BstXI fragment from exon 1 (hatched 
region) to a eDNA fragment via the BstXI site. Arrows denote PCR 
primer positions used in the analysis in Fig. 4. (B) Haman NK-3 
genomic sequence. Dideoxy s~iuencing was carried out on double- 
stranded plasmid template and exon-intron boundaries were assi~ned 
by comparison with NK-3 eDNA as well as other NK genes. All 
seq:,¢:,cc shown comes from gcnomic DNA with the exception of the 
initial 17 bp on exon 2 (underlined) which was obtained from eDNA. 
used as an NK-3 selective radioligand and saturation 
binding indicated a single class of binding site with a K,, 
of 9.6 nM and expression of approximately 17,000 re- 
ceptors/cell (Fig. 3A). Specific [3H]Senktide binding was 
>90% of total and this was displaced by a range of 
neurokinin agonists with the relative rank-order of 
potency senktide=NKB>Eledoisin>NKA=SP (Fig. 
3B) reflecting the pharmacological characteristics ex- 
pected of a NK-3 receptor subtype [2,11,12,28]. Con- 
centrations of neuropeptide inhibiting specific 
[3H]senktide binding by 50% were: senktide, 26.9__.7.4 
nM (,=4); NKB, 32__.8.9 nM (n=4); eledoisin, 
424.8+160.6 nM (n=4); NKA, 2729__.!111 nM (n=3), 
and SP, 3097_+253 nM (n=3). In addition to binding, 
this NK.3 expressing clone was found to respond to 
neurokinin stimulation with an immediate (<2 s) but 
transient increase in cytosolic Ca 2. concentration with 
a maximum 6-fold increase detected within 20 s. Basal 
levels were re-established after 2-3 rain (data not 
shown). This response also displayed pharmacological 
characteristics expected of an NK-3 receptor and 
mirrored the binding data with the rank-order 
senktide=NKB>Eledoisin>NKA=SP (Fig. 3C). As 
reported previously for the bovine NK-2 receptor ex- 
pressed in CHO cells [20], the human NK-3 receptor 
also mediated a 2-3-fold increase in [;H]arachidonic 
acid release and this response showed identical pharma- 
cological characteristics as obtained by radioligand 
binding and Ca"* mobil'-lzatioa (data not shown). 
The most interesting observation from these studies 
is that while eledoisin is approximately 15-fold less 
potent than either senktide or NKB at the human NK-3 
receptor (Fig. 3B and C), all three neuropeptides display 
a similarly high affinity for the NK-3 receptor in some 
animal tissue preparations uch as guinea pig ileum [5]. 
This potentially distinct pharmacological property of 
human NK-3 may account in part for the reported ina- 
bility to detect this receptor in human brain using 
1 ?0 
tlkl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  MD VLPVD D S. l t l  THT E 
l~k2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  MGTCDIVTEAMZSSG'PBB 
~k3 MAZ LPAAETWI  D GGGGVGADA~II~LTA~ LAAGAATGAVE TGIfLQLLD~AGI~ LSS S ~ SALGLPVRJ~P~ S~ 
71 140 
..... A Q V AA T I VTB V W M AE V 
HTTGZTA SH ;~L AT  LAL  L T A R Z L,% LC A& 
WR.tILTH~YV~ SW~TR-LWR LAYGVVV&VRV'L~H LT'JTW Z Z ~TVT I~IFLVNLk I~ G D ~ H T L  
TM Z TM ZZ 
141 210 
T V N Y LF K a A V F H G V CV V 
F v S NZ RAFT  L M V A Vii FG PS A ~ LV 
VNF ZYALHS EWI'FGAHYCI~FoI~FP ~ TAVF~ T ~S M TAY~VI~RYMAZ Z DP L ~ P R L B E T A ~  
TM ZZZ TM 
221 280 
L GT T ET S W I~CE H I'~Z'/EIW C TV Z FL VZ XA Y 
I,% S F 'k~TMD~ A K WA DSGG~TLLL  LV  A Z FL  AV FVA SVZ L RR& 
~TKVMPGRTLCFVQWPEGPKQHF, ,  TYHT ~ TL~r~CPPrLTMQTTTT I 'VGTT]~ 
TMY 
281 350 
SS R VS V C F F L PY h~D ~ F ZH 
V H~AHGA~LRH G K F T VII L L GSFQEDZYC:H F L 
TM VI  ~ e l l  
351 420 
D L n O ~I%GD EG H S ~T.  G V ~ S L TTZBTVVGAR 
fl S RL C WVTPTKE K TP TSLST  . .  ,~¢STE TLFMAG TA~ 
S TM'n~ T T Y CCl h'KI~FRAGFKR~FRWC¥¥ ZKVs SYDELELKT TRFHPNR~S SM'fT~TRR~.SMTVVFDPMD 
421 46S 
EEEPEDGP AT~..B~L TB C8 8D TMTE~F £ NVLS . . . . . .  
BEA ~GF.,AGRP;~DGSGLW GYGLLA~T TIiVET . . . . . . . . . . . . . . .  
~TTRSS~T~PS~C,  CS~SRS~h~S~ZSS~Y~SVDZYb 
Fig. 2, Comparison of the amino acid sequences for the three human N K gent, Human NK-I [22l and NK-2 [23] amino acid sequences ~ aligned 
with NK-3 for maximal s~lt~nce hemology. A dot indicates no amino acid in that position whereas an open space in NK-I or NK-2 indicates 
the same amino acid as in NK-3. 
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Fi B. 3, Pharmacological characteristics oP human NK-3 r=:cptor ex. 
pressed in CHO cells. (A) [~H]Senktide saturation binding to CHO 
cells. Non-Sl~Ciflc binding was determined in the presence of I pM 
NKB. Points are the mean of triplicate determinations and is re- 
presentative of 3 experiments, (B) Competition by several neurokinin 
agonists for specific [~H]senktide binding which was employed at con- 
ccntrntioas bgtwcen 2,5 and 3.8 aM, Points are the means of 3 (NKA 
and SP) or 4 (senktide, NKB and eledoisin) determinations each per- 
formed in tripticate. ICm values were calculated and are reported in 
text. (C) lntracellular Ca ~÷ concentrations were measured usingfura2 
levels increased as a funetio=~ of agonist concentration. Resting levels 
wore normally 80-120 aM. Points are the means of 2 (NKA), 3 (SP 
and NKB), 4 (eledoisin) or 6 (senktide) determinations. 
[~:~I]eledoisin [6]. Indeed, although NK-3 receptors 
were undetectable in primate brain or spinal cord using 
[~:~I]eledoisin [6], [~H]senktide has been used recently to 
map successfully NK-3 receptors in monkey tissue [2]. 
To establish the pattern of NK-3 receptor expression 
in human tissues we performed PCR analysis on mRNA 
extracted from brain and some peripheral tissues. Using 
NK-3 specific oligonucleotid¢ primers 2 and 3 (Fig. 1), 
all brain regions that were examined showed the pres- 
ence of NK-3 mRNA (Fig. 4). We also observed lesser 
amplification of the NK-3 specific fragment with 
mRNA from some peripheral tissues, notably kidney 
with longer film exposures revealing avery weak signal 
from lung and colon (not shown). Our inability to detect 
NK-3 receptor mRNA by Northern blotting of the 
RNA from all of the above tissues uggests an extremely 
low abundance for this mRNA (data not shown). 
In summary, we have isolated and characterised the 
human NK-3 gone and shown that while this receptor 
exhibits expected pharmacological characteristics 
towards the physiological neurokinins NKB, SP and 
NKA, it exhibits an unexpectedly low affinity for ele- 
doisin. We also show that the human NK-3 receptor 
gone is expressed in many areas of human brain and 
selectively in some peripheral tissues. 
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